Table 1.
Dysregulated microRNAs in the tissue of predominantly HBV-related HCC.
| miRNAs |
Dysregulation type |
Fold change | Case vs. control | Samples details | References | |
|---|---|---|---|---|---|---|
| Size and HBV status | Underlying cirrhosis % (n) | |||||
| miR-18a | Up-regulated | 0.585a | HCC vs. ANT | 78 HCC (62 HBV) | 51% (40/78) | (17) |
| Up-regulated | 3.223b | HCC vs. ANT | 22 HCC (20 HBV) | NA | (18) | |
| miR-21 | Up-regulated | 2.29a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) |
| Up-regulated | 3.67b | HCC vs. ANT | 115 HCC (101 HBV) | 51% (59/115) | (20) | |
| Up-regulated | NA | HCC vs. ANT | 148 HCC (82 HBV) | 41% (45/109) | (21) | |
| Up-regulated | NA | HCC vs. ANT | 31 HBV-HCC | NA | (22) | |
| Up-regulated | NA | HCC vs. ANT | 24 HBV-DNs, 29 small HBV-HCC nodules, 38 HBV-ANTs | 92% (22/24) in DNs 93% (27/29) in HCC | (23) | |
| Up-regulated | 3.72b | HCC vs. ANT | 42 HBV-HCC | NA | (24) | |
| miR-221 | Up-regulated | 1.51a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) |
| Up-regulated | NA | HCC vs. ANT | 135 HCC (96 HBV) | 95% (128/135) | (25) | |
| Up-regulated | 4.00b | HCC vs. ANT | 115 HCC (101 HBV) | 51% (59/115) | (20) | |
| Up-regulated | NA | HCC vs. ANT | 31 HBV-HCC | NA | (22) | |
| Up-regulated | NA | HCC vs. ANT | 24 HBV-DNs, 29 small HBV-HCC Nodules, 38 HBV-ANTs | 92% (22/24) in DNs 93% (27/29) in HCC | (23) | |
| Up-regulated | 1.57a | HCC vs. ANT | 78 HCC (62 HBV) | 51% (40/78) | (17) | |
| miR-222 | Up-regulated | 1.41a | HCC vs. ANT | 78 HCC (62 HBV) | 51% (40/78) | (17) |
| Up-regulated | 4.44b | HCC vs. ANT | 115 HCC (101 HBV) | 51% (59/115) | (20) | |
| Up-regulated | 4.964b | HCC vs. ANT | 22 HCC (20 HBV) | NA | (18) | |
| Up-regulated | NA | HCC vs. ANT | 42 HCC (33 HBV), 6 HCV, 3 NBNC-HCC | 85% (28/33) | (26) | |
| miR-224 | Up-regulated | NA | HCC vs. ANT | 24 HBV-DNs, 29 small HBV-HCC Nodules, 38 HBV-ANTs | 92% (22/24) in DNs 93% (27/29) in HCC | (23) |
| Up-regulated | 27.231b | HCC vs. ANT | 22 HCC (20 HBV) | NA | (18) | |
| Up-regulated | 0.903a | HCC vs. ANT | 78 HCC (62 HBV) | 51% (40/78) | (17) | |
| miR-26a | Down-regulated | 0.37 b | HCC vs. ANT | 455 HCC (412 HBV) | 88% (400/455) | (27) |
| Down-regulated | −1.59a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) | |
| miR-101 | Down-regulated | NA | HCC vs. ANT | 25 HCC (20 HBV), 20 HC (HBV negative) | 72% (18/25) | (28) |
| Down-regulated | NA | HCC vs. HC HCC vs. CHB HCC vs. LC |
67 HBV-HCC, 61 HBV-LC, 79 CHB, 30 Normal control | NA | (29) | |
| Down-regulated | 0.214b | HCC vs. ANT | 22 HCC (20 HBV) | NA | (18) | |
| Down-regulated | −0.958a | HCC vs. ANT | 78 HCC (62 HBV) | 51% (40/78) | (17) | |
| miR-122 | Down-regulated | −1.67a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) |
| Down-regulated | NA | HCC vs. ANT | 97 HCC (84 HBV) | NA | (30) | |
| Down-regulated | NA | HCC vs. ANT, HBV-HCC vs. non-HBV-HCC |
142 HCC (103 HBV) | 58% (82/142) | (31) | |
| Down-regulated | NA | HCC vs. ANT | 24 HBV-DNs, 29 small HBV-HCC Nodules, 38 HBV-ANTs | 92% (22/24) in DNs 93% (27/29) in HCC | (23) | |
| Down-regulated | 0.60b | Venous metastases vs. solitary tumors | 214 HBV-HCC | 93% (199/214) | (32) | |
| miR-125b | Down-regulated | −0.893a | HCC vs. ANT | 78 HCC (62 HBV) | 51% (40/78) | (17) |
| Down-regulated | NA | HCC vs. ANT | 97 HCC (84 HBV) | NA | (30) | |
| Down-regulated | 0.58b | Venous metastases vs. solitary tumors | 214 HBV-HCC | 93% (199/214) | (32) | |
| miR-145 | Down-regulated | NA | HCC vs. ANT LGDN vs. ANT HGDN vs. ANT |
24 HBV-DNs, 29 small HBV-HCC Nodules, 38 HBV-ANTs | 92% (22/24) in DNs 93% (27/29) in HCC | (23) |
| 0.28b | HCC vs. ANT | 42 HBV-HCC | NA | (24) | ||
| miR-145-5P | Down-Regulated | −2.39a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) |
| miR-199a | Down-regulated | 0.149b | HCC vs. ANT | 22 HCC (20 HBV) | NA | (18) |
| Down-regulated | NA | HCC vs. ANT | 97 HCC (84 HBV) | NA | (30) | |
| miR-199a-5P | Down-regulated | −4.51a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) |
| miR-199a-3P | Down-regulated | −2.78a | HCC vs. ANT | 100 HCC (58 HBV, 8 HCV, 27 NBNC, 27 Unknown) | 46% (46/100) | (19) |
| miR-199b | Down-regulated | NA | HCC vs. ANT LGDN vs. ANT HGDN vs. ANT |
24 HBV-DNs, 29 small HBV-HCC Nodules, 38 HBV-ANTs | 92% (22/24) in DNs 93% (27/29) in HCC | (23) |
| miR-200a | Down-regulated | NA | HCC vs. ANT | 120 HCC (97 HBV) | 78% (93/120) | (33) |
| Down-regulated | 0.421b | HCC vs. ANT | 101 HCC (71 HBV) | NA | (34) | |
| Down-regulated | 0.522b | HCC vs. ANT | 95 HCC (78 HBV) | 47% (45/95) | (35) | |
| miR-223 | Down-regulated | −1.92a | HCC vs. ANT | 100 HCC (58 HBV) | 46% (46/100) | (19) |
| Down-regulated | 0.267b | HCC vs. ANT | 22 HCC (20 HBV) | NA | (18) | |
| Down-regulated | 0.20b | HCC vs. ANT | 42 HCC (33 HBV), 6 HCV, 3 NBNC-HCC | 85% (28/33) | (26) | |
Fold changes were based on the original report;
a
Log2 fold change.
b
Regular fold change.
ANT, adjacent non-cancerous tissue; CHB, chronic hepatitis B; DN, dysplastic nodules; HBV, hepatitis B virus; HC, healthy control; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HGDN, high-grade dysplastic nodule; LC, liver cirrhosis; LGDN, low-grade dysplastic nodule; NA, not available; NBNC, non-HBV non-HCV.